Buy Cagrilintide: The Amylin Analogue, the Trials, and the Stack Nobody Has Tested
Cagrilintide is a research amylin analogue tested alone and with semaglutide: what the phase 2 trial found, why the retatrutide combination is unstudied.
Research use only. Scientific background on cagrilintide's mechanism, the published trial data and the evidence gap around combining it with other peptides. Sold here strictly as a laboratory research material, not for administration to a person or animal. Nothing below is a dose, a titration schedule, an injection site, a reconstitution volume or ratio, or a same-syringe answer.
TL;DR: what cagrilintide is, what it was tested as, what it was never tested with
The molecule: a lipidated, long-acting amylin analogue built to fix the short half-life of predecessor pramlintide, which needs three daily injections (PMID 34288673). The monotherapy result: the phase 2 trial produced 6.0 to 10.8% weight loss across doses versus 3.0% on placebo, the top dose producing numerically greater weight loss than liraglutide 3.0 mg (PMID 34798060). CagriSema is a product, not a stack: cagrilintide 2.4 mg plus semaglutide 2.4 mg, developed and trialled as one fixed combination, not two vials a researcher assembles. The zero-trial finding: no trial has combined cagrilintide with retatrutide, and cagrilintide plus tirzepatide have only appeared as competing arms, never co-administered. What you can verify on a vial: identity by CAS number, a batch certificate at /coa, and the reconstitution class. Not a dose, not a stack, not a purity percentage in prose.
Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.
First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.
USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, pH 6.2 to 6.4) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
GIP/GLP-1/Glucagon agonists and metabolic pathways
What cagrilintide actually is
Cagrilintide is a lipidated, fatty-acid-acylated analogue of human amylin, engineered for a long half-life; predecessor pramlintide needs three injections a day because it clears quickly. The design challenge, in the words of its own medicinal chemists: "A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort" (PMID 34288673, Kruse T et al., J Med Chem 2021;64(15):11183-11194). Fatty-acid acylation is what stretches the half-life far enough for the weekly dosing interval the trials used.
Amylin is a beta-cell hormone co-secreted with insulin. A narrative review describes it as reducing food intake, slowing gastric emptying and reducing postprandial glucagon, via the area postrema relayed to the forebrain (PMID 16697020, Lutz TA, Physiol Behav 2006). That review is rodent-dominated and narrative, with no human trial numbers to read into it.
The amylin receptor is not a single gene product: it is the calcitonin receptor (CTR) paired with a receptor-activity-modifying protein (RAMP), giving three phenotypes, AMY1a, AMY2a and AMY3a (PMID 15494035). Which RAMP gives the highest-affinity phenotype varies with the CTR splice isoform and host cell line (PMID 10871296, Tilakaratne N et al., J Pharmacol Exp Ther 2000;294(1):61-72), in-vitro pharmacology, not a statement about human tissue.
A phase 1b study co-administering cagrilintide (0.16 to 4.5 mg weekly) with semaglutide 2.4 mg measured a cagrilintide half-life of 159 to 195 hours, median time to peak 24 to 72 hours (PMID 33894838, Enebo LB et al., Lancet 2021;397(10286):1736-1748), a combination PK/safety study, not monotherapy data, and the reason cagrilintide is dosed weekly rather than daily like pramlintide.
What the monotherapy trial measured
The trial designed around cagrilintide on its own is a phase 2, 26-week, randomised, double-blind, placebo- and active-controlled dose-finding trial, 706 participants total, arms of roughly 100 to 102 each: cagrilintide at 0.3, 0.6, 1.2, 2.4 and 4.5 mg, liraglutide 3.0 mg, and placebo (PMID 34798060, Lau DCW et al., Lancet 2021;398(10317):2160-2172, NCT03856047).
- Weight change
- -3.0% (-3.3 kg)
- Weight change
- -6.0% to -10.8% (-6.4 to -11.5 kg)
- Weight change
- -10.8% (-11.5 kg)
- Weight change
- -9.0% (-9.6 kg)
Weight loss rose with dose, and the top cagrilintide dose numerically outperformed liraglutide 3.0 mg.
Gastrointestinal adverse events occurred in 41 to 63% of cagrilintide participants versus 32% on placebo, nausea 20 to 47% versus 18%. Administration-site reactions were dose-dependent, 13.0% to 42.6% versus 13.1% on liraglutide and 3.0% on placebo: 13 of 100 in the 0.6 mg arm versus 43 of 101 in the 4.5 mg arm. Serious adverse events were infrequent, 2.0% to 6.9% by arm with no trend across doses, and there were no deaths.
Anti-drug antibodies were common and dose-dependent, reaching roughly half of participants in some arms by week 32 in the posted trial results for NCT03856047, and not associated with reduced weight loss. Two phase 1 findings in one line each: no clinically relevant QTc prolongation in a dedicated thorough-QT study, n=105 (PMID 39279639), and no meaningful pharmacokinetic change in renal or hepatic impairment (PMID 42228334).
What this trial was and was not
NCT03856047 is the only published standalone efficacy trial of cagrilintide. It is not the only place the molecule stands alone: REDEFINE 1 carried a cagrilintide-only arm inside a combination trial, reaching -11.5% at week 68, and a dedicated monotherapy phase 3 programme is running now. RENEW 1 (NCT07220642, 300 participants) and RENEW 2 (NCT07220759, 330 participants, type 2 diabetes) both test once-weekly cagrilintide against placebo over 64 weeks and were listed as active and no longer recruiting when this article was written, with no results posted. A third, RENEW 4 (NCT07745504), was registered and not yet recruiting. NCT03856047 was not a phase 3 registration trial and reports no efficacy outcomes beyond 26 weeks, and the comparator is liraglutide, not semaglutide or tirzepatide.
CagriSema is a product, not a stack
CagriSema is Novo Nordisk's fixed once-weekly combination of cagrilintide 2.4 mg plus semaglutide 2.4 mg, developed and trialled from the outset as one product, not two peptides a researcher combines independently.
In REDEFINE 1 (n=3417, 68 weeks), the treatment-policy estimand, the primary analysis counting everyone regardless of adherence, showed CagriSema at -20.4% versus placebo at -3.0%, a difference of -17.3 points. In the same trial, semaglutide alone reached -14.9% and cagrilintide alone reached -11.5%. Gastrointestinal adverse events occurred in 79.6% of CagriSema versus 39.9% on placebo (PMID 40544433, Garvey WT et al., N Engl J Med 2025).
One honesty point circulates online in simplified form: the widely quoted 22.7% figure is not the primary result. It is the trial-product estimand, which models the effect that would be expected if every randomised participant had adhered to treatment, rather than a calculation restricted to those who did. The primary, treatment-policy result is 20.4%. Both numbers are real, and it matters which is cited. Full breakdown: our REDEFINE analysis.
A 2026 meta-analysis (3 RCTs, n=3545) found cagrilintide monotherapy carried a higher serious-adverse-event risk than semaglutide, RR 1.83 (95% CI 1.03-3.24), while CagriSema showed a raised risk of administration-site conditions, RR 3.27 (95% CI 1.27-8.46) (PMID 41834765); full analysis in the monotherapy meta-analysis.
In the head-to-head phase 3 trial NCT06131437, open-label, 809 participants, CagriSema did not meet the pre-specified non-inferiority margin against tirzepatide 15 mg (sponsor topline announcement; the registry entry carries no posted results). Unposted, unpublished: topline and registry information, not published evidence.
Regulatory status: a US New Drug Application for CagriSema was submitted 18 December 2025. Cagrilintide, alone or as CagriSema, is not an approved medicine anywhere.
The question the forums actually ask
The recurring question is not really about CagriSema. It is whether a researcher should put standalone cagrilintide next to retatrutide once retatrutide's own appetite suppression fades, on the theory that adding an amylin pathway to a triple agonist would restore satiety.
The direct answer: no clinical trial, registered or published, has ever combined cagrilintide with retatrutide. This is checkable, not an assumption: a ClinicalTrials.gov API v2 search for cagrilintide AND retatrutide, run 26 August 2026, returns zero studies. The same search for cagrilintide alone returns 43 studies, confirming the search works.
Cagrilintide and tirzepatide fare no better, never co-administered in a registered trial; they appear together only as competing arms in three head-to-head studies (NCT06131437, NCT06221969, NCT06534411), each participant receiving one compound or the other, never both.
The "amylin plus GLP-1 is additive" idea circulating on forums traces to review language, not a trial result. Reviewers wrote that the two mechanisms "appear to have an additive effect on appetite reduction" (PMID 36883831, D'Ascanio AM et al., Cardiol Rev 2024;32(1):83-90), a description of a plausible mechanism, written about the combination that became CagriSema. It has never been tested with, and should never be transferred to, retatrutide.
What that leaves is a mechanism plausible on paper and a combination entirely unstudied in practice: two different statements, and the gap between them is the actual state of the evidence.
What we do not answer here
- Starting dose and titration. Administration questions for laboratory research materials, not human use.
- Whether to lower another compound's dose when adding this one. No trial has tested this combination.
- Same-syringe questions. Outside the scope of a research-material listing.
- Reconstitution volumes or acid concentration. Laboratory-procedure detail, not general-audience content.
- Unit-to-mg conversions from a pen. Pen-based dosing is for approved medicines; this is not one.
- Premixed multi-compound vials. We do not comment on formulation or use.
What you can verify on a research vial
A cagrilintide research vial has a checkable identity independent of anything above: an acylated analogue of the 37-amino-acid hormone amylin, CAS number 1415456-99-3, molecular formula C194H312N54O59S2. Each lot carries its own batch certificate, published at /coa; the testing method is described at /purity. Purity percentages and batch numbers are not printed here because they change per incoming lot; current figures live on those pages.
On reconstitution, cagrilintide sits in our acid-start class: not a plain bacteriostatic-water dissolve like most peptides we list. That is a fact about solubility behaviour, not a procedure. See bacteriostatic water and bacteriostatic vs acetic acid vs sterile water. No volumes, ratios or acid concentration here.
Storage follows the same class-level statement as other lyophilised peptides we list: protected from light and moisture, no fixed duration, since stability depends on each lot's own documentation.
Match the lot to the vial
The certificate must carry the same lot or batch code printed on the vial in your hand.
Read identity and content, not appearance
A CoA should confirm the molecule by mass and report measured content or purity for that lot. Colour and clarity are not a substitute for that data.
Read the water
Because cagrilintide is in the acid-start class, the diluent's own documentation, not a default bacteriostatic-water assumption, tells you what you are dissolving into.
Do not use a sensation as a quality test
No published study ties injection-site sensation to cagrilintide's identity or purity.
Where cagrilintide sits next to what else we list
Positioned honestly, standalone cagrilintide is a weaker weight-loss agent than semaglutide in the one trial that put both in the same design: REDEFINE 1, cagrilintide alone -11.5% against semaglutide alone -14.9%, same population. Not a case against amylin-pathway research; it is what the one direct comparison shows. Broader comparison: Retatrutide vs Cagrilintide vs AOD-9604.
Amylin analogue on its own
The GLP-1 side of the catalogue
First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.
Reconstitution and storage
USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, pH 6.2 to 6.4) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Dilute 0.6% acetic-acid diluent at around pH 3.8, for reconstituting research peptides that stay cloudy in plain bacteriostatic water, such as IGF-1 LR3 and Cagrilintide. Two-step protocol. Each vial is sealed and ready to use.
Transparent storage box with 10 individual compartments for 1-3 ml peptide vials. Stackable, fridge-friendly, travel-safe. Ideal for organising bacteriostatic water, GLP-1, BPC-157, and similar vials.
Frequently asked questions
Sources
- Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. PMID 34288673. https://pubmed.ncbi.nlm.nih.gov/34288673/
- Lutz TA. Amylinergic control of food intake. Physiol Behav. 2006. PMID 16697020. https://pubmed.ncbi.nlm.nih.gov/16697020/
- Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004. PMID 15494035. https://pubmed.ncbi.nlm.nih.gov/15494035/
- Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther. 2000;294(1):61-72. PMID 10871296. https://pubmed.ncbi.nlm.nih.gov/10871296/
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. Lancet. 2021;397(10286):1736-1748. PMID 33894838. https://pubmed.ncbi.nlm.nih.gov/33894838/
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID 34798060. https://pubmed.ncbi.nlm.nih.gov/34798060/
- Thorough QT study of cagrilintide. PMID 39279639. https://pubmed.ncbi.nlm.nih.gov/39279639/
- Pharmacokinetics of cagrilintide in renal and hepatic impairment. PMID 42228334. https://pubmed.ncbi.nlm.nih.gov/42228334/
- Garvey WT, et al. CagriSema for the Treatment of Obesity (REDEFINE 1). N Engl J Med. 2025. PMID 40544433. https://pubmed.ncbi.nlm.nih.gov/40544433/
- Cagrilintide monotherapy versus semaglutide: a meta-analysis of randomised controlled trials. PMID 41834765. https://pubmed.ncbi.nlm.nih.gov/41834765/
- D'Ascanio AM, et al. Amylin and GLP-1 Receptor Agonism in Obesity Management. Cardiol Rev. 2024;32(1):83-90. PMID 36883831. https://pubmed.ncbi.nlm.nih.gov/36883831/
- CagriSema versus tirzepatide in adults with obesity. ClinicalTrials.gov NCT06131437. https://clinicaltrials.gov/study/NCT06131437
- Novo Nordisk. CagriSema head-to-head topline announcement versus tirzepatide (company release; no peer-reviewed publication). https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501
- RENEW 1 (NCT07220642), RENEW 2 (NCT07220759) and RENEW 4 (NCT07745504), phase 3 cagrilintide monotherapy trials, no results posted. https://clinicaltrials.gov/study/NCT07220642 , https://clinicaltrials.gov/study/NCT07220759 , https://clinicaltrials.gov/study/NCT07745504
- CagriSema versus tirzepatide, trial registration. ClinicalTrials.gov NCT06221969. https://clinicaltrials.gov/study/NCT06221969
- CagriSema versus tirzepatide, trial registration. ClinicalTrials.gov NCT06534411. https://clinicaltrials.gov/study/NCT06534411
- Cagrilintide dose-finding trial registration. ClinicalTrials.gov NCT03856047. https://clinicaltrials.gov/study/NCT03856047
Research use only. Cagrilintide is supplied for laboratory research, not for human or animal administration, not as a cosmetic, not as a medicine. Nothing here is a dosing, injection, reconstitution or medical instruction.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.